Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 6, 2010, Pages 539-546

  Brophy, Donald F ^a   Martin, Erika J ^a   Nolte, Melinda E ^a   Kuhn, Janice G ^a   Barrett, J Christian ^a   Ezban, Mirella ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

hemophilia; NN1731; platelets; recombinant factor VIIa; thrombin generation; thromboelastography

Indexed keywords

HEMOSTATIC AGENT; NN 1731; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; EX VIVO STUDY; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

ADULT; AGED; BLOOD COAGULATION; BLOOD PLATELETS; CASE-CONTROL STUDIES; CLOT RETRACTION; FACTOR VII; FACTOR VIIA; HEMOPHILIA A; HEMOSTASIS; HUMANS; KINETICS; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; YOUNG ADULT;

EID: 77955927200     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833b63e9     Document Type: Article

References (25)

1. Hedner U. Factor VIIa and its potential therapeutic use in bleedingassociated pathologies. Thromb Haemost 2008; 100:557-562.
2. Siddiqui MA, Scott LJ. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs 2005; 65:1161-1177.
3. Hayashi T, Tanaka I, Shima M, Yoshida K, Fukuda K, Sakurai Y, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10:397-400.
4. Hedner U. Recombinant factor VIIa: its background, development and clinical use. Curr Opin Hematol 2007; 4:225-229. (Pubitemid 46597607)
5. Carr ME Jr, Martin EJ. Evolving techniques for monitoring clotting in plasma and whole blood samples. Clin Lab 2004; 50:539-549.
6. Persson E, Bak H, Østergaard A, Olsen OH. Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. Biochem J 2004; 379:497-503.
7. Persson E. Variants of recombinant factor VIIa with increased intrinsic activity. Semin Hematol 2004; 41:89-92.
8. Møss J, Scharling B, Ezban M, Møller Sørensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost 2009; 7:299-305.
9. Allen GA, Persson E, Campbell A, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27:683-689.
10. Sørensen B, Persson E, Ingerslev J. Factor VIIA analogue (V158D/E296 V/ M298Q-FVIIa) normalises clot formation in whole blood from patients with sever haemophilia A. Br J Haematol 2007; 137:158-165.
11. Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Carr ME. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 2007; 13:533-541.
12. Vá radi K, Turecek PL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004; 10 (Suppl. 2):17-21.
13. Dargaud Y, Bordet JC, Lienhart A, Negrier C. Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII. Semin Hematol 2008; 45 (Suppl. 1):S72-S73.
14. Sørensen B, Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol 2004; 41 (Suppl 1):140-144.
15. Johansen RF, Sørensen B, Ingerslev J. Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy. Haemophilia 2006; 12:190-197.
16. Young G, Ebbesen LS, Viuff D, Di Paola J, Konkle BA, Negrier C, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19:276-282.
17. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34:612.
18. Carr ME Jr. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophys 2003; 38:55-78.
19. Carr ME, Martin EJ, Kuhn JG, Spiess BD. Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT). J Thromb Haemost 2003; 1:1977-1983.
20. HaemoscopeTM (Internet). (place unknown); c1998-2007. http:// www.haemoscope.com. [Accessed 26 February 2009]
21. Sørensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2:102-110.
22. Larsen OH, Clausen N, Persson E, Ezban M, Ingerslev J, Sørensen B. Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant rfactor VIIa, and a potent factor VIIa analogue. Br J Haematol 2009; 144:99-106.
23. Sørensen B, Johansson PI, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1:551-558.
24. Dehmel H, Werwitzke S, Trummer A, Ganser A, Tiede A. Thromboelastographic monitoring of recombinant factor VIIa in acquired hemophilia. Haemophilia 2008; 14:736-742.
25. Johansson PI, Jacobsen N, Viuff D, Olsen EH, Rojkjaer R, Andersen S, et al. Differential clot stabilising effects of rFVIIa and rFXIII-A2 in whole blood from thrombocytopenic patients and healthy volunteers. Br J Haematol 2008; 143:559-569.